The American Heart Association (AHA) has announced a comprehensive initiative aimed at expanding access to clinical trials for transthyretin amyloid cardiomyopathy (ATTR-CM), a progressive heart condition that disproportionately affects older adults and certain racial and ethnic groups.
The program seeks to address significant healthcare disparities by developing targeted strategies to increase awareness, education, and participation in cutting-edge medical research. ATTR-CM is characterized by a misshapen protein buildup in the heart that can impair cardiac function and potentially lead to heart failure.
Key components of the initiative include creating educational materials, hosting national webinars, and establishing a referral network to help identify potential clinical trial participants. The first webinar, "Understanding Amyloidosis & Emerging Therapeutic Frontiers," will feature experts in cardiology and gene therapy and is scheduled for June 18.
Dr. Michelle Kittleson, an AHA volunteer and professor of medicine at Cedars-Sinai, emphasized the importance of connecting underserved populations with medical innovations. "Too many people remain unaware of or disconnected from lifesaving cardiovascular clinical trials," she noted.
The initiative, supported financially by Intellia Therapeutics, aims to close knowledge gaps and improve access to early diagnosis and emerging treatments for cardiac amyloidosis across diverse geographical and socioeconomic backgrounds.
